Navigation Links
ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
Date:10/31/2012

CAMBRIDGE, Mass., Oct. 31, 2012 /PRNewswire/ -- ViThera Pharmaceuticals, Inc, a developer of novel therapeutics based on engineered probiotic bacteria, announced today the publication of breakthrough data validating its approach for the delivery of elafin in treating gastrointestinal inflammation. The results were published today by the journal Science Translational Medicine and show use of recombinant probiotic and non-pathogenic food-strain bacteria to deliver elafin, a protein designed to protect human mucosal tissue during inflammation. The publication by senior author Nathalie Vergnolle and ViThera co-founder Philippe Langella describes a series of preclinical experiments successfully validating elafin as a novel treatment approach with future applications for human inflammatory bowel disease (IBD).

ViThera's President, Johannes Fruehauf, commented, "We are excited about the recognition that this publication entails and we congratulate Nathalie and Philippe on this important achievement." ViThera has obtained worldwide exclusive rights to the technology and is developing it further towards validation in clinical trials in close collaboration with Dr. Vergnolle and Dr. Langella. ViThera's VT301 program, currently in preclinical development, focuses on restoring and maintaining the integrity of the gut epithelium in patients with IBD by delivering elafin. This treatment is designed to help patients with active disease achieve remission faster and patients in remission to avoid flare-ups. VT301 is expected to enter clinical trials in two years for patients with mild to moderate ulcerative colitis.

About ViThera Pharmaceuticals

ViThera is a startup biotechnology company based in Cambridge, Massachusetts. Its research combines innovative molecular biology with the benefits of probiotics to create therapeutics for a variety of chronic diseases, including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. ViThera i
'/>"/>

SOURCE ViThera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
3. New magnetic-field-sensitive alloy could find use in novel micromechanical devices
4. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
5. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
6. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
7. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
8. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
11. Novel method to make nanomaterials discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Navitas, a leading Regulatory Service provider, today announced that ... in Bogota, Colombia . Navitas, expansion into ... by Colombia , the third largest economy in ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... clients to communicate with Navitas regulatory professionals in close to or the ...
(Date:7/3/2015)... ... July 03, 2015 , ... The ... companies and professional service industries alike-- typically known for its consummate professionalism-- embarks ... a good cause and break from their day jobs. , "Our motto has ...
(Date:7/3/2015)... 2015 Forskere kan ... på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab for ... i Wien .  ... forskere og videnskabsmænd foretaget af Ludwig Boltzmann ... for sundhedsvidenskaben manglen på incitamenter til at ...
(Date:7/2/2015)... ALTO, Calif. (PRWEB) , ... July 02, 2015 , ... ... to improve an individual’s quality of sleep, launched its Indiegogo campaign on June 23. ... functionality: Luzi's voice command technology makes it effortless to use, while the integration of ...
Breaking Biology Technology:Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3The Alexander Group Declares Their Independence with a Bit of Levity 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3
... , , EMERYVILLE, Calif., Aug. 3 ... release financial results for the second quarter of fiscal year 2009 ended ... a conference call and web cast to review the financial results on ... Interested parties can access the call by dialing (800) 860-2442 or ...
... ROCKVILLE, Md., Aug. 3 Human Genome Sciences, ... of its public offering of 26,697,250 newly issued shares of ... $14.00 per share, which includes 3,482,250 shares sold upon exercise ... The net proceeds to the Company from the offering ...
... CHICAGO, Aug. 3 Known medically as atopic dermatitis ... rashes.(1) Scratching the affected area of skin may ... fluid, and crusting of the skin.(2) Immuno-modulators called topical ... patients with mild, moderate or severe eczema(3) who fail ...
Cached Biology Technology:Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009 2Human Genome Sciences Announces Closing of Public Offering 2Human Genome Sciences Announces Closing of Public Offering 3Five Questions About Protopic (tacrolimus) Ointment 2Five Questions About Protopic (tacrolimus) Ointment 3Five Questions About Protopic (tacrolimus) Ointment 4
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... brain study finds major differences between women with serious ... crucial to stress and emotions. , The study ... specific alterations within the brain -- specifically in the ... the brain's natural pain and stress-reduction system. The findings ...
... at Harvard University have developed a computer model ... and predict how small proteins fold into three-dimensional, ... better understand the abnormal protein aggregation underlying some ... evolved and how proteins recognize correct biochemical partners ...
... The golden age of dinosaur discovery is yet upon us, ... In a forthcoming issue of the Proceedings of the National ... the diversity of discoverable dinosaurs upward by 50%, offering a ... found. His findings also add evidence that dinosaur populations ...
Cached Biology News:New brain-chemistry differences found in depressed women 2New brain-chemistry differences found in depressed women 3Comprehensive model is first to map protein folding at atomic level 2Good times ahead for dinosaur hunters, according to U of Penn scientist's dinosaur census 2Good times ahead for dinosaur hunters, according to U of Penn scientist's dinosaur census 3